Updates

Press Release

Anthem Biosciences Limited logo
Anthem Biosciences LimitedANTHEM · Filed with the exchange

Anthem reports Q1FY27 consolidated revenue of ₹418.2 Cr, EBITDA ₹175.5 Cr (39.6% margins), and PAT ₹119.9 Cr (27.1% margins). Management notes Q1 reflects delivery timing shifts; strong demand and higher deliveries are expected in H2, sustaining revenue growth and industry-leading margins.

Read the original filing(PDF)

No comments yet. Be the first.

More from Anthem Biosciences Limited

All announcements